Trulieve Earnings 2026 Q1: Financial Results & Analysis

Executive Summary

Trulieve Cannabis Corp. (TCNNF) filed an 8-K with the SEC on May 7, 2026, signaling the release of its first quarter 2026 financial results—a critical benchmark for the largest vertically integrated multi-state operator in the U.S. cannabis industry. The Form 8-K filing, which includes Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), marks Trulieve's formal disclosure of Q1 2026 performance to investors and regulators. As the dominant cannabis retailer in Florida with expanding operations across eleven states, Trulieve's quarterly earnings serve as a bellwether for the broader U.S. cannabis market's health amid ongoing federal prohibition and state-level regulatory evolution. The company's Q1 results arrive at a pivotal moment: federal rescheduling discussions continue, interstate commerce remains prohibited, and state markets face margin compression from oversupply and increased competition. Trulieve's performance in this quarter will reveal how the company navigates Florida's mature medical market, integrates recent acquisitions, manages cultivation efficiency, and positions itself for potential federal reform. With over 190 dispensaries nationwide and approximately $850 million in annual revenue as of fiscal year 2025, Trulieve's earnings provide essential insights into operational execution, cash flow generation, and strategic positioning within the constrained capital environment that defines the cannabis sector in 2026.

Why This Matters

Trulieve's Q1 2026 earnings impact thousands of stakeholders across the cannabis ecosystem, from 8,000+ employees to millions of medical patients, institutional investors managing billions in cannabis exposure, and policymakers evaluating market maturation. Trulieve operates the largest single-state footprint in Florida, serving over 500,000 registered medical marijuana patients through approximately 120 dispensaries. The company's performance directly affects product availability, pricing, and access for patients managing conditions from chronic pain to PTSD. Florida's medical program, which generated over $2 billion in sales in 2025, depends heavily on Trulieve's cultivation capacity and distribution network. For investors, Trulieve represents one of the few profitable U.S. multi-state operators, trading on the Canadian Securities Exchange and OTC markets with a market capitalization fluctuating between $800 million and $1.2 billion through early 2026. Institutional holders including ETF providers, pension funds with cannabis exposure, and dedicated cannabis investment vehicles scrutinize quarterly results to assess sector viability. The company's ability to generate positive EBITDA and operating cash flow distinguishes it from capital-burning competitors. The broader cannabis industry watches Trulieve's margins, same-store sales growth, and operational metrics as indicators of market health. With wholesale cannabis prices declining 15-30% year-over-year in mature markets, Trulieve's vertical integration strategy—controlling cultivation, processing, and retail—offers a test case for sustainable profitability. The company's performance influences capital allocation decisions across the sector, affecting everything from debt financing availability to M&A valuations. State regulators in Florida and ten other jurisdictions monitor Trulieve's compliance, tax contributions, and market share. Florida alone collected over $150 million in cannabis-related taxes in 2025, with Trulieve contributing an estimated 30-40% of that total. The company's operational stability affects state revenue projections and regulatory policy decisions. Federal policymakers and reform advocates view Trulieve's earnings as evidence for or against cannabis industry legitimacy. Sustained profitability and compliance strengthen arguments for federal legalization or banking access, while operational challenges fuel prohibition advocates' concerns.

Background and History

Trulieve's journey from a single Florida dispensary in 2015 to the nation's most profitable MSO reflects both strategic execution and the unique regulatory landscape of state-legal cannabis markets.

Founding and Florida Dominance (2015-2018)

Trulieve Cannabis Corp. was founded in 2015 following Florida's passage of the Compassionate Medical Cannabis Act of 2014, which authorized low-THC cannabis for limited medical conditions. CEO Kim Rivers, a former healthcare attorney, secured one of Florida's initial five vertically integrated licenses. The company opened its first dispensary in Tallahassee in July 2016, positioning itself as a patient-focused medical provider rather than a recreational brand. Florida voters approved Amendment 2 in November 2016, expanding medical marijuana access to a broader range of qualifying conditions and creating a market estimated to reach 500,000+ patients. Trulieve capitalized on first-mover advantage, rapidly expanding cultivation capacity and opening dispensaries across the state while competitors struggled with capital constraints and regulatory compliance. By December 2018, Trulieve operated 27 Florida dispensaries and commanded approximately 50% market share in the state's emerging medical program.

Public Listing and Geographic Expansion (2018-2020)

Trulieve completed a reverse takeover transaction in September 2018, listing on the Canadian Securities Exchange under ticker symbol TRUL (later TCNNF on U.S. OTC markets). The public listing provided access to capital markets despite U.S. federal prohibition, which prevented traditional U.S. exchange listings. The company raised approximately $70 million in its initial public offering, funding continued Florida expansion and entry into new markets. The company entered California, Massachusetts, and Connecticut through a combination of license applications and strategic acquisitions between 2019 and 2020. Trulieve acquired Life Essence dispensary in Massachusetts in October 2019 and PurePenn LLC in Pennsylvania in November 2020, establishing footholds in limited-license Eastern markets with favorable supply-demand dynamics. By year-end 2020, Trulieve operated 78 dispensaries across six states, with Florida representing approximately 90% of revenue. The company reported $521 million in revenue for fiscal 2020, achieving profitability while most competitors burned cash to fund expansion.

Harvest Health Acquisition (2021)

Trulieve announced its transformational acquisition of Harvest Health & Recreation in May 2021, valued at approximately $2.1 billion in stock. The transaction, completed in October 2021, added operations in Arizona, Maryland, Pennsylvania, and other states, immediately diversifying Trulieve's geographic footprint and doubling its dispensary count to over 150 locations. The Harvest integration presented operational challenges, including disparate technology systems, cultivation inefficiencies at acquired facilities, and brand rationalization across multiple markets. Trulieve spent 2022 integrating operations, closing underperforming locations, and standardizing cultivation protocols. Revenue reached $1.2 billion in fiscal 2022, but margins compressed as the company absorbed integration costs and navigated Arizona's recreational market launch, which triggered wholesale price declines.

Market Maturation and Operational Focus (2023-2025)

Trulieve shifted strategy in 2023 toward operational efficiency and margin improvement rather than geographic expansion. The company closed approximately 20 underperforming dispensaries, consolidated cultivation facilities, and implemented automation in processing operations. Florida remained the profit engine, contributing an estimated 60-65% of revenue and substantially higher margins than newer markets. Florida's adult-use ballot initiative (Amendment 3) in November 2024 failed to achieve the required 60% threshold, receiving approximately 56% support. The defeat preserved Florida's medical-only framework through at least 2026, providing Trulieve continued regulatory protection from unlimited competition. The company had contributed over $50 million to the Smart & Safe Florida campaign supporting the initiative, betting that early-mover advantage would translate to adult-use market dominance. Federal rescheduling discussions intensified in 2024-2025, with the DEA considering moving cannabis from Schedule I to Schedule III under the Controlled Substances Act. Rescheduling would provide significant tax relief under IRC Section 280E, which currently prohibits cannabis businesses from deducting ordinary business expenses. Trulieve's effective tax rate exceeded 70% in recent years due to 280E limitations, making rescheduling potentially transformative for profitability. By early 2026, Trulieve operated approximately 190 dispensaries across eleven states, with cultivation facilities totaling over 4 million square feet. The company employed over 8,000 people and served hundreds of thousands of patients weekly.

Key Players

Trulieve Leadership

Kim Rivers, Chief Executive Officer, has led Trulieve since founding, maintaining strategic focus on profitability over growth-at-any-cost strategies that bankrupted competitors. Rivers' healthcare background shaped Trulieve's patient-centric approach and regulatory compliance emphasis. Her leadership through the Harvest integration and margin compression period of 2022-2023 proved critical to maintaining profitability. Alex D'Amico serves as Chief Financial Officer, managing capital allocation, investor relations, and financial reporting. D'Amico's focus on cash flow generation and debt management positioned Trulieve as one of few MSOs with investment-grade balance sheet metrics.

Regulatory Bodies

Florida Department of Health Office of Medical Marijuana Use (OMMU) regulates Trulieve's largest market, controlling licensing, compliance, and product standards. OMMU's regulatory framework, which limits vertical integration licenses to a small number of operators, has protected Trulieve's market position while constraining competition. The agency oversees approximately 800,000 registered patients as of early 2026. The Securities and Exchange Commission (SEC) receives Trulieve's financial disclosures despite cannabis remaining federally illegal. Form 8-K filings for earnings releases fall under Items 2.02 (financial results) and 7.01 (Regulation FD disclosure), ensuring equal information access for all investors. State regulatory agencies in Pennsylvania, Arizona, Massachusetts, Maryland, West Virginia, Connecticut, and other Trulieve markets each impose distinct compliance requirements, testing standards, and operational constraints that affect profitability and expansion strategy.

Competitors

Curaleaf Holdings, Green Thumb Industries, Verano Holdings, and Cresco Labs represent Trulieve's primary MSO competitors, each pursuing different geographic and strategic approaches. Curaleaf operates the most dispensaries nationwide (over 150), while Green Thumb emphasizes wholesale brands. Verano focuses on limited-license markets, and Cresco combines retail with wholesale cultivation. Trulieve's Florida dominance and profitability focus distinguish it from competitors prioritizing national footprint. Single-state operators in Florida including Surterra Wellness (now Parallel), Curaleaf Florida, and MÜV (Verano) compete directly in Trulieve's core market, though none approach Trulieve's 30-40% market share.

Investors and Analysts

Institutional investors including AdvisorShares Pure US Cannabis ETF (MSOS), Amplify Seymour Cannabis ETF (CNBS), and dedicated cannabis funds hold significant Trulieve positions. Analyst coverage from Canaccord Genuity, Cantor Fitzgerald, Stifel, and other firms shapes investor perception and stock valuation. Analyst consensus estimates for Q1 2026 anticipated revenue of approximately $210-220 million with adjusted EBITDA margins of 28-32%.

Legal and Regulatory Framework

Trulieve operates within a complex matrix of state-legal authorization and federal prohibition, creating unique compliance, tax, and operational constraints unknown in other industries.

Federal Prohibition

The Controlled Substances Act of 1970 classifies cannabis as a Schedule I substance, defining it as having no accepted medical use and high abuse potential. This classification creates cascading legal consequences: cannabis businesses cannot deduct ordinary expenses under IRC Section 280E, cannot access traditional banking services under federal money laundering statutes, face import/export prohibitions, and operate under constant risk of federal enforcement. The Cole Memorandum (2013-2018) provided informal federal enforcement forbearance for state-legal operators, but Attorney General Jeff Sessions rescinded it in January 2018. Subsequent congressional appropriations riders (Rohrabacher-Farr/Blumenauer-McClintock amendments) have prohibited DOJ from spending funds to interfere with state medical programs, providing limited protection. Rescheduling proceedings initiated in 2023 could move cannabis to Schedule III by late 2026 or early 2027, eliminating 280E tax burdens and potentially enabling limited banking access. However, rescheduling would not legalize cannabis or permit interstate commerce, maintaining state-by-state market fragmentation.

State Frameworks

Florida operates under the Florida Medical Marijuana Legalization Initiative (Amendment 2, approved 2016) and implementing statutes in Florida Statutes Section 381.986. The framework requires vertical integration, limits licenses to operators meeting strict financial and operational criteria, and caps dispensary numbers per license holder based on patient count. Trulieve holds one of approximately 25 active medical marijuana treatment center (MMTC) licenses. Florida's regulatory structure prohibits smokable flower sales (later overturned by courts), restricts advertising, requires physician certification for patients, and mandates seed-to-sale tracking through Biotrack THC. The state imposes no sales tax on medical marijuana but requires licensing fees and regulatory assessments. Other Trulieve markets employ varied frameworks: Pennsylvania operates a medical-only program with limited licenses and vertical integration requirements; Arizona transitioned to adult-use in 2021 with existing medical operators receiving priority licensing; Massachusetts allows both medical and adult-use with separate licensing pathways and local approval requirements.

Securities Regulation

Trulieve files periodic reports with the SEC despite cannabis's federal illegality, utilizing the OTC Markets framework for U.S. investors and Canadian Securities Exchange listing for primary trading. The company files Forms 10-K (annual reports), 10-Q (quarterly reports), and 8-K (current reports) under Securities Exchange Act requirements. Form 8-K Item 2.02 specifically addresses "Results of Operations and Financial Condition," requiring disclosure of material financial information outside regular reporting cycles. Item 7.01 covers "Regulation FD Disclosure," ensuring public release of information that might otherwise be selectively disclosed. Item 9.01 requires filing of financial statements and exhibits. These filings do not constitute SEC endorsement of cannabis businesses but provide investor protection through mandatory disclosure and anti-fraud provisions.

State-by-State Breakdown

Florida

Florida represents approximately 60% of Trulieve's revenue and substantially higher margins than any other market, making it the company's profit engine and strategic priority. Trulieve operates approximately 120 dispensaries across Florida, serving over 500,000 registered patients from a total state registry exceeding 800,000. The company's cultivation facilities in Quincy and other locations total over 3 million square feet, producing flower, concentrates, vapes, edibles, and topicals under the Trulieve, Muse, and other brands. Florida's medical-only framework limits competition compared to adult-use markets, supporting higher retail prices (typically $40-50 per eighth of flower versus $25-35 in adult-use markets). Vertical integration requirements create barriers to entry, protecting incumbent operators like Trulieve from unlimited competition. The failure of Amendment 3 in November 2024 preserved this framework through at least 2026, though adult-use advocates plan another ballot initiative for 2028. Patient count growth has slowed to single-digit percentages as the market matures, pressuring same-store sales growth.

Pennsylvania

Pennsylvania's limited-license medical program provides Trulieve with protected market position across approximately 20 dispensaries, though regulatory constraints limit profitability compared to Florida. Trulieve entered Pennsylvania through the PurePenn acquisition in 2020 and Harvest integration in 2021, establishing cultivation and dispensary operations. Pennsylvania's medical program serves approximately 400,000 patients statewide, with Trulieve commanding an estimated 8-12% market share. Regulatory challenges include prohibition on vertical integration (requiring separate cultivation and dispensary licenses), restrictive product forms (no flower sales until 2018), and local municipality opt-out provisions. Adult-use legislation has stalled repeatedly in the state legislature despite gubernatorial support, leaving the medical-only framework intact.

Arizona

Arizona's transition to adult-use in 2021 created margin compression and competitive intensity, making it Trulieve's most challenging major market despite strong revenue contribution. Trulieve inherited approximately 15 Arizona dispensaries through the Harvest acquisition, operating under the Harvest brand in the Phoenix metro area and other locations. Arizona's adult-use launch triggered wholesale price declines of 30-40% as cultivation capacity expanded rapidly, compressing retail margins. The state's dual-license framework (separate medical and adult-use) and unlimited dispensary licensing for existing medical operators created intense competition. Trulieve has focused on operational efficiency and brand differentiation to maintain market share in this commoditizing environment.

Massachusetts

Massachusetts offers adult-use upside with approximately 10 Trulieve dispensaries, though high taxes and local control create operational complexity. Trulieve operates medical and adult-use dispensaries in Massachusetts, navigating the state's local approval requirements, which grant municipalities veto power over cannabis businesses. The combined state excise tax (10.75%) and local taxes (up to 3%) plus standard sales tax create total tax burdens approaching 20%, affecting price competitiveness. Supply-demand dynamics have improved as initial oversupply corrected through 2024-2025, supporting margin recovery. Massachusetts represents a growth opportunity if Trulieve can secure additional local approvals and expand dispensary count.

Other Markets

Trulieve maintains smaller operations in Maryland, West Virginia, Connecticut, and other states, collectively contributing approximately 15-20% of revenue. These markets provide geographic diversification and potential growth options but require ongoing investment in compliance, local management, and market-specific strategies.

Market and Business Implications

Trulieve's Q1 2026 earnings will reveal how the company navigates industry-wide challenges including margin compression, capital constraints, and federal uncertainty while maintaining its profitability advantage over competitors.

Multi-State Operator Landscape

The U.S. MSO sector entered 2026 facing structural challenges: wholesale cannabis prices declined 15-30% year-over-year in mature markets due to cultivation oversupply; retail competition intensified as states issued unlimited licenses; and capital markets remained largely closed to cannabis operators due to federal prohibition. These dynamics forced industry consolidation, with smaller operators selling assets or declaring bankruptcy. Trulieve's vertical integration strategy—controlling cultivation, processing, and retail—provides margin protection compared to single-function operators. The company's cultivation cost per gram, estimated at $200-250 per pound all-in, positions it competitively even as wholesale prices approach $800-1,000 per pound in Florida (down from $1,500+ in 2020). Same-store sales growth, a critical retail metric, has slowed across the industry as markets mature. Trulieve's Florida same-store sales likely grew low-single-digits in Q1 2026, pressuring overall revenue growth. The company must balance price competitiveness with margin preservation, a tension evident in promotional activity and product mix shifts toward higher-margin concentrates and vapes.

Wholesale Pricing Dynamics

Wholesale cannabis prices function as the industry's key commodity indicator, affecting vertically integrated operators' transfer pricing and margin calculations. Florida wholesale prices for quality flower remained relatively stable at $1,000-1,200 per pound through early 2026 due to limited license competition, while Arizona and California prices fell to $600-800 per pound. Trulieve's vertical integration allows internal transfer pricing that optimizes tax efficiency and margin allocation between cultivation, processing, and retail segments. However, external wholesale sales to other dispensaries (where permitted) face market-rate pricing pressure. Concentrate and extract pricing has held more stable than flower, supporting Trulieve's product mix evolution toward higher-margin vape cartridges, live resin, and other processed products. These items typically generate 40-50% gross margins versus 30-40% for flower.

Capital Markets and Financing

Cannabis operators face unique capital constraints due to federal prohibition: no access to traditional bank loans, no U.S. exchange listings, limited institutional investor participation, and high-cost debt financing. Trulieve has navigated this environment through operational cash flow generation, avoiding the dilutive equity raises that plague unprofitable competitors. The company's senior secured notes, issued at interest rates of 8-9%, represent relatively favorable terms in the cannabis sector, where debt often carries 12-15% rates. Maintaining positive cash flow and manageable leverage ratios (debt-to-EBITDA below 3x) provides financial flexibility for opportunistic M&A or capital investment. Potential federal rescheduling could unlock traditional banking relationships and lower-cost capital, transforming industry economics. Trulieve's strong balance sheet positions it to capitalize on distressed asset acquisitions if smaller operators fail.

280E Tax Impact

IRC Section 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses, limiting deductions to cost of goods sold. This creates effective tax rates of 70%+ for profitable cannabis operators, dramatically reducing net income. Trulieve's 280E burden likely exceeded $100 million annually in recent years. Rescheduling to Schedule III would eliminate this constraint, potentially doubling net income without any operational changes. The company's Q1 2026 earnings materials likely address rescheduling timeline expectations and financial impact scenarios.

What Experts Say

Industry analysts, policy observers, and market participants view Trulieve's earnings as a critical indicator of MSO sector health and operational execution quality. Cannabis industry analysts emphasize Trulieve's unique position as the only consistently profitable large-scale MSO, attributing success to Florida market dominance and disciplined capital allocation. Analyst consensus heading into Q1 2026 earnings anticipated revenue of $210-220 million, representing modest year-over-year growth of 3-5%, with adjusted EBITDA margins of 28-32%. These expectations reflect market maturation and competitive pressure balanced against operational efficiency gains. Equity research perspectives highlight Trulieve's valuation discount compared to Canadian licensed producers, despite superior profitability metrics. The discount reflects federal illegality risk, limited institutional ownership, and OTC market liquidity constraints. Analysts note that federal rescheduling or SAFE Banking Act passage could trigger valuation multiple expansion of 50-100%. Policy experts observe that Trulieve's sustained profitability contradicts prohibitionist arguments that legal cannabis markets inevitably fail. The company's tax contributions, employment numbers, and compliance record provide empirical evidence for legalization advocates. Conversely, Trulieve's market concentration in Florida raises concerns about oligopoly dynamics and barriers to entry in limited-license states. Financial analysts focusing on operational metrics emphasize inventory turnover, cultivation efficiency, and retail productivity as key performance indicators. Trulieve's inventory turns of approximately 4-5x annually suggest efficient supply chain management, while revenue per square foot of retail space averaging $3,000-4,000 indicates strong store productivity. Market observers note competitive dynamics in Florida, where Curaleaf, Verano, and other operators have increased promotional activity and price competition through early 2026. Trulieve's ability to maintain market share without destructive price wars will signal brand strength and customer loyalty. Debt market participants view Trulieve as one of few cannabis credits with sustainable coverage ratios and asset backing. The company's real estate holdings, cultivation facilities, and retail locations provide tangible collateral, while positive cash flow supports debt service. Credit analysts estimate Trulieve could access additional debt financing at rates 200-300 basis points below sector averages. Regulatory compliance experts highlight Trulieve's track record of limited violations or enforcement actions across multiple state jurisdictions as evidence of operational maturity. This compliance history reduces regulatory risk and supports license renewal confidence.

What's Next

Trulieve's Q1 2026 earnings release triggers a sequence of investor communications, regulatory filings, and strategic decisions that will shape the company's trajectory through the remainder of 2026.

Immediate Calendar

The May 7, 2026 Form 8-K filing indicates earnings release timing, with investor conference calls typically scheduled within 24-48 hours of SEC filing. Trulieve management will host analyst and investor Q&A sessions addressing financial results, operational metrics, and forward guidance. SEC filing deadlines require Form 10-Q for Q1 2026 within 45 days of quarter-end (March 31, 2026), placing the deadline in mid-May 2026. The 10-Q will provide detailed financial statements, management discussion and analysis, and risk factor updates beyond the 8-K summary. Investor presentations and non-deal roadshows typically follow earnings releases, with management meeting institutional investors and analysts to discuss results and strategy. These meetings provide qualitative context beyond numerical results.

Regulatory Decision Points

Federal rescheduling proceedings continue through 2026, with DEA final rule publication expected in late 2026 or early 2027. Trulieve's earnings materials and investor communications will likely address rescheduling timeline expectations and financial impact modeling. The company's tax planning and capital allocation strategies depend heavily on rescheduling timing. Florida's 2026 legislative session (January-March) concluded without adult-use legalization, preserving the medical framework through at least 2027. However, adult-use advocates plan another ballot initiative for November 2028, requiring signature gathering through 2026-2027. Trulieve's strategic positioning and capital allocation will reflect adult-use probability assessments. SAFE Banking Act prospects remain uncertain in the divided Congress, with passage potentially enabling traditional banking relationships and lower capital costs. Trulieve monitors federal legislative developments closely, as banking access would transform operational efficiency and financing options.

Strategic Priorities

Trulieve's stated strategic priorities for 2026 emphasize operational efficiency, margin improvement, and selective market expansion. The company continues integrating Harvest-acquired assets, closing underperforming locations, and standardizing cultivation protocols across facilities. Florida market defense remains paramount, requiring competitive pricing, product innovation, and customer experience excellence to maintain 30-40% market share against intensifying competition. Trulieve's brand portfolio expansion, including Muse and other targeted brands, supports market segmentation and customer retention. Geographic expansion focuses on limited-license markets with favorable supply-demand dynamics rather than unlimited-license adult-use states with margin compression. Pennsylvania, Maryland, and similar markets offer growth potential with regulatory protection. Product mix evolution toward higher-margin concentrates, vapes, and infused products continues, requiring processing capacity investment and brand development. These categories typically generate 40-50% gross margins versus 30-40% for flower. Technology and automation investments target cultivation efficiency, retail operations, and customer experience. Automated trimming, climate control optimization, and inventory management systems reduce costs and improve consistency.

M&A and Capital Allocation

Trulieve's strong balance sheet and cash flow generation position it for opportunistic acquisitions of distressed assets or strategic licenses. The company has signaled interest in Pennsylvania expansion, additional Florida dispensary licenses (if available), and selective entry into new limited-license markets. Capital allocation priorities balance growth investment with shareholder returns. While cannabis companies rarely pay dividends due to growth capital needs and federal tax constraints, Trulieve's profitability could eventually support return of capital programs. Debt refinancing opportunities may emerge if federal rescheduling or banking reform reduces cannabis-specific risk premiums. Trulieve could potentially refinance existing 8-9% notes at 5-6% rates in a normalized regulatory environment.

Further Reading

• Trulieve Cannabis Corp. SEC Filings — EDGAR database, CIK 0001754195: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001754195
• Florida Department of Health Office of Medical Marijuana Use — regulatory framework, patient statistics, and MMTC license information: https://knowthefactsmmj.com/about/
• Controlled Substances Act, 21 U.S.C. § 801 et seq. — federal cannabis scheduling and prohibition framework
• Internal Revenue Code Section 280E — tax deduction limitations for Schedule I/II businesses
• Florida Statutes Section 381.986 — Medical Marijuana Treatment Centers statutory framework
• Trulieve Investor Relations — corporate presentations, earnings archives, and financial guidance: investor.trulieve.com
• Cannabis industry trade publications including MJBizDaily, Marijuana Moment, and Green Market Report for sector analysis and competitive intelligence
• Viridian Capital Advisors Cannabis Deal Tracker — M&A activity, capital raises, and market trends
• New Frontier Data and BDSA market research reports — state-by-state sales data, pricing trends, and market forecasts
• Congressional Research Service reports on cannabis rescheduling, SAFE Banking Act, and federal policy developments